Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study.

Popat R, Beksac M, Dimopoulos MA, Gatt ME, Gay F, Jo JC, Kapoor P, Katodritou E, Kortüm KM, Ling S, Nagarajan C, Suzuki K, Qiu L, Onishi M, Ku G, Dail M, Mukherjee N, Ross JA, Badawi MA, Fusco MJ, Dobkowska E, Arriola E, Bueno OF, Bahlis NJ, Iida S, Moreau P, Valent J, Mateos MV

Open source

DOI: 10.1200/jco-25-00924
Published: 2026 Jan 20
Container: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/jco-25-00924,
  title = {Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study.},
  author = {Popat R and Beksac M and Dimopoulos MA and Gatt ME and Gay F and Jo JC and Kapoor P and Katodritou E and Kortüm KM and Ling S and Nagarajan C and Suzuki K and Qiu L and Onishi M and Ku G and Dail M and Mukherjee N and Ross JA and Badawi MA and Fusco MJ and Dobkowska E and Arriola E and Bueno OF and Bahlis NJ and Iida S and Moreau P and Valent J and Mateos MV},
  year = {2026},
  journal = {Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  doi = {10.1200/jco-25-00924},
  url = {https://doi.org/10.1200/jco-25-00924}
}

RIS

TY  - JOUR
TI  - Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study.
AU  - Popat R
AU  - Beksac M
AU  - Dimopoulos MA
AU  - Gatt ME
AU  - Gay F
AU  - Jo JC
AU  - Kapoor P
AU  - Katodritou E
AU  - Kortüm KM
AU  - Ling S
AU  - Nagarajan C
AU  - Suzuki K
AU  - Qiu L
AU  - Onishi M
AU  - Ku G
AU  - Dail M
AU  - Mukherjee N
AU  - Ross JA
AU  - Badawi MA
AU  - Fusco MJ
AU  - Dobkowska E
AU  - Arriola E
AU  - Bueno OF
AU  - Bahlis NJ
AU  - Iida S
AU  - Moreau P
AU  - Valent J
AU  - Mateos MV
PY  - 2026
JO  - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
DO  - 10.1200/jco-25-00924
UR  - https://doi.org/10.1200/jco-25-00924
ER  -

APA

R, P., M, B., MA, D., ME, G., F, G., JC, J., P, K., E, K., KM, K., S, L., C, N., K, S., L, Q., M, O., G, K., M, D., N, M., JA, R., MA, B., MJ, F., E, D., E, A., OF, B., NJ, B., S, I., P, M., J, V., & MV, M. (2026). Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. https://doi.org/10.1200/jco-25-00924

Source records

pubmed · retrieved 2026-09-26T07:19:35.281Z